Back to discover
Disease

Brain Stem Neoplasms

Clinical development underwayEmerging research
MeSHBrain Stem Neoplasms
1
Publications
3
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Carmustineapproved

Approval — Carmustine is indicated n adults in the following malignant neoplasms as a single ag… (2018)

Clinical trials

3 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
3
All trials
0
Active
0
Late-stage
2
Completed
Recently completed

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Phase 1 · Completed · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma

Phase 2 · Completed · Ann & Robert H Lurie Children's Hospital of Chicago

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2018emaApproval — Carmustine· Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes3
  • Brain Stem Neoplasms1
  • Diffuse Intrinsic Pontine Glioma1
  • Glioma1
Leading journals1
  • Cancer cell1
Leading researchers8
  • Alonso MM1
  • Anderson AC1
  • Ausejo-Mauleon I1
  • Becher OJ1
  • Collantes M1
  • De Andrea C1
  • de Biagi-Junior CAO1
  • de la Nava D1
Affiliations (unnormalised)6
  • Center for Genetic Medicine Research1
  • Dana-Farber Boston Children's Cancer and Blood Disorders Center1
  • Division of Oncology and Children's Research Center1
  • Evergrande Center for Immunologic Diseases1
  • Health Research Institute of Navarra (IdiSNA)1
  • James L. Winkle College of Pharmacy1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.

Identifiers
MeSHBrain Stem Neoplasms
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.